Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Placebo|DRUG: Fulvestrant
Sponsor: Pfizer
Collaborators: AstraZeneca